Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
01 October 2014Website:
http://www.notablelabs.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 30 Oct 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
NTBL Latest News
Society of Hematologic Oncology (SOHO) session to highlight volasertib program Phase 2 volasertib AML program expected to begin in the coming months FOSTER CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd.
Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd.
Notable Labs (NTBL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
There is increasing optimism about Notable Labs (NTBL) earnings potential, leading to its upgrade to a Zacks Rank #2 (Buy) and the possibility of the stock moving higher.
FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer therapies based on its Predictive Precision Medicine Platform (PPMP), today announced that the Company will present two posters related to its PPMP platform at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.
FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer therapies based on its Predictive Precision Medicine Platform (PPMP), today announced that the Company will present two posters related to its PPMP platform at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.
What type of business is Notable Labs?
Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California. On October 13, 2024, Notable Labs, Ltd. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
What sector is Notable Labs in?
Notable Labs is in the Healthcare sector
What industry is Notable Labs in?
Notable Labs is in the Biotechnology industry
What country is Notable Labs from?
Notable Labs is headquartered in United States
When did Notable Labs go public?
Notable Labs initial public offering (IPO) was on 01 October 2014
What is Notable Labs website?
https://www.notablelabs.com
Is Notable Labs in the S&P 500?
No, Notable Labs is not included in the S&P 500 index
Is Notable Labs in the NASDAQ 100?
No, Notable Labs is not included in the NASDAQ 100 index
Is Notable Labs in the Dow Jones?
No, Notable Labs is not included in the Dow Jones index
When was Notable Labs the previous earnings report?
No data
When does Notable Labs earnings report?
Next earnings report date is not announced yet